Projects

Head of Department
PharmDr. Katarína Bauerová, PhD., DrSc.

International

Current
  • Application of bionic hydrogel enriched with selected natural compounds for repair of articular cartilage lesion.
    Program: Bilateral - other
    Duration: 1. 2. 2022 – 31. 12. 2023
  • Anti-inflammatory effects of natural compounds isolated from Vietnam medicinal plants
    Program: Bilateral - other
    Duration: 1. 4. 2020 – 30. 6. 2023
Finished
  • Collaboration on a complex pharmacological assessment of inflammatory diseases of the musculo-skeletal system and gastrointestinal tract on experimental animal models
    Program: Bilateral - other
    Duration: 1. 1. 2019 – 31. 12. 2022
  • Anti-inflammatory effect of astaxanthin, sulforaphane and Crocus sativus extract evaluated in two rodent models of age related diseases.
    Program: Inter-academic agreement
    Duration: 1. 1. 2018 – 30. 6. 2021
  • Evaluation of Quercetin and Green Tea in combination with Methotrexate for arthritis therapy (Acronym: PhytoArt 2.0)
    Program: Bilateral - other
    Duration: 1. 1. 2016 – 31. 12. 2017
  • -
    Program: Bilateral - other
    Duration: 1. 1. 2013 – 31. 12. 2015
  • Role of the systemic inflammatory processes in the development of oxidative stress in the brain of arthritic subjects. Evaluation of experimental therapy based on new carnosine preparations
    Program: Bilateral - other
    Duration: 1. 1. 2013 – 31. 12. 2015
  • In vitro and in vivo models of arthritic processes for studying the mechanisms of inflammation and oxidative stress link-up. New perspectives for arthritis therapy
    Program: Bilateral - other
    Duration: 1. 1. 2010 – 31. 12. 2012
  • Regulation of cytokine synthesis during inflammation develoment in brain and other tissues
    Program: Bilateral - other
    Duration: 1. 1. 2010 – 31. 12. 2012

National

Current
  • The contribution of new nano-carrier drug delivery systems to the enhancement of the anti-inflammatory effect of D-limonene, phellandrene, isoborneol and chrysophanol studied in vivo (2/0091/23
    Program: VEGA
    Duration: 1. 1. 2023 – 31. 12. 2026
  • -
    Program: VEGA
    Duration: 1. 1. 2020 – 31. 12. 2023
Finished
  • -
    Program: VEGA
    Duration: 1. 1. 2019 – 31. 12. 2021
  • -
    Program: SRDA
    Duration: 1. 7. 2016 – 30. 6. 2020
  • -
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2018
  • Study of combination of immunosuppressive treatment and substances affecting redox balance of organism on animal models of rheumatoid arthritis
    Program: VEGA
    Duration: 1. 1. 2011 – 31. 12. 2014
  • Cellular and molecular aspects of pharmacological regulation of neutrophil pro-inflammatory activity
    Program: SRDA
    Duration: 9. 9. 2008 – 30. 6. 2011
  • -
    Program: VEGA
    Duration: 1. 1. 2008 – 31. 12. 2010
  • New pharmacological approaches affecting rheumatoid arthritis studied on adjuvant arthritis
    Program: VEGA
    Duration: 1. 1. 2008 – 31. 12. 2010
  • Molecular mechanisms of new drugs influencing oxidative stress - important ethiopathogenetic factor of numerous diseases
    Program: SRDA
    Duration: 1. 9. 2006 – 31. 10. 2009
  • Effect of immunostimulators and their combination with methotrexate on adjuvant arthrithis in rats
    Program: SRDA
    Duration: 1. 5. 2006 – 30. 4. 2009
  • Specific antagonists myocardial production and secretion of p roinflammatory cytokines(IC), expression of mitogenic vasopressor peptides (MP), polyferation and pathological remodelation after myocardial infarction (MI) and in chroni heart failure (CHF)
    Program: VEGA
    Duration: 1. 1. 2005 – 1. 12. 2007
  • Effects of antioxidants and substances afecting the imunita systém studied in vivo using a model of adjuvant arthritis
    Program: VEGA
    Duration: 1. 1. 2005 – 1. 12. 2007
Employees